Healthcare Industry News: bone graft
News Release - August 16, 2011
NovaBone Announces New Moldable Bone GraftThis Expands Existing Portfolio of Bioactive Synthetic bone grafts for Orthopedic Surgery
JACKSONVILLE, Fla.--(Healthcare Sales & Marketing Network)-- NovaBone Products announces the introduction of MacroPor-Si+ to its portfolio of biologically active bone graft substitutes. NovaBone Products develops bone graft substitutes based on advancements in biomedical engineering that meet the specialized needs of both orthopedic and dental surgeons.
MacroPor-Si+ was developed to serve as a moldable material that can be fitted to the size and shape of the grafting site. The main component of the device is a calcium phosphosilicate having a continuous macroporous structure. This material is suspended in a rapidly-absorbable binder. The open structure of the porous component allows for rapid vascularization and mineralization. With time, the device is completely absorbed and replaced by new bone.
The addition of MacroPor-Si+ marks a continuation of NovaBone Product's strategy to expand its portfolio of bioactive bone graft substitutes. “We are proud to offer surgeons multiple options for their bone grafting needs, and continue to pioneer silicate-based grafting options,” said Dennis McBride, Vice President of Sales and Marketing.
NovaBone Products is a leading producer and marketer of bioactive synthetic bone graft substitutes. NovaBone Products pioneered silicon and calcium ion controlled release products that stimulate and accelerate the regeneration of cortical and cancellous bone. The company markets on a worldwide basis from its offices in Florida, New Jersey, and Shanghai, PRC.
Since its inception in 2002, the company has developed numerous formulations and delivery systems of its patented, bioactive technology platform. The product portfolio stimulates accelerated bone growth for the repair of osseous defects throughout the skeletal system.
Source: NovaBone Products
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.